New day, new NOVO study 😌but positive today:

"Novo Nordisk reports that the Phase 2 study with Amycretin showed significant weight loss and HbA1c reduction in type 2 diabetes - Amycretin resulted in a statistically significant weight loss of up to 14.5% after 36 weeks."

$NVO (+1,34 %)
$NOVO B (+1,02 %)